Geoff S Higgins

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8652006/publications.pdf

Version: 2024-02-01

42 papers

2,564 citations

361045 20 h-index 288905 40 g-index

43 all docs 43 docs citations

43 times ranked

 $\begin{array}{c} 4412 \\ \text{citing authors} \end{array}$

#	Article	lF	CITATIONS
1	Oxidative Phosphorylation as an Emerging Target in Cancer Therapy. Clinical Cancer Research, 2018, 24, 2482-2490.	3.2	687
2	Ultra-High Dose Rate (FLASH) Radiotherapy: Silver Bullet or Fool's Gold?. Frontiers in Oncology, 2019, 9, 1563.	1.3	302
3	The anti-malarial atovaquone increases radiosensitivity by alleviating tumour hypoxia. Nature Communications, 2016, 7, 12308.	5.8	173
4	Polî, inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance. Nature Communications, 2021, 12, 3636.	5.8	159
5	A Small Interfering RNA Screen of Genes Involved in DNA Repair Identifies Tumor-Specific Radiosensitization by POLQ Knockdown. Cancer Research, 2010, 70, 2984-2993.	0.4	116
6	Overexpression of <i>POLQ</i> Confers a Poor Prognosis in Early Breast Cancer Patients. Oncotarget, 2010, 1, 175-184.	0.8	100
7	A role for human homologous recombination factors in suppressing microhomology-mediated end joining. Nucleic Acids Research, 2016, 44, 5743-5757.	6.5	83
8	Drug radiotherapy combinations: Review of previous failures and reasons for future optimism. Cancer Treatment Reviews, 2015, 41, 105-113.	3.4	78
9	Dose and Fractionation in Radiation Therapy of Curative Intent for Non-Small Cell Lung Cancer: Meta-Analysis of Randomized Trials. International Journal of Radiation Oncology Biology Physics, 2016, 96, 736-747.	0.4	78
10	The Future of Radiobiology. Journal of the National Cancer Institute, 2018, 110, 329-340.	3.0	76
11	NVP-BEZ235 and NVP-BGT226, dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitors, enhance tumor and endothelial cell radiosensitivity. Radiation Oncology, 2012, 7, 48.	1.2	73
12	Beyond PARPâ€"POLÎ, as an anticancer target. Science, 2018, 359, 1217-1218.	6.0	70
13	Improving the Predictive Value of Preclinical Studies in Support of Radiotherapy Clinical Trials. Clinical Cancer Research, 2016, 22, 3138-3147.	3.2	68
14	T-LAK cell-originated protein kinase (TOPK): an emerging target for cancer-specific therapeutics. Cell Death and Disease, 2018, 9, 1089.	2.7	60
15	CDK1 inhibition sensitizes normal cells to DNA damage in a cell cycle dependent manner. Cell Cycle, 2018, 17, 1513-1523.	1.3	59
16	Tumor pH and Protein Concentration Contribute to the Signal of Amide Proton Transfer Magnetic Resonance Imaging. Cancer Research, 2019, 79, 1343-1352.	0.4	52
17	Mitochondrial Inhibitor Atovaquone Increases Tumor Oxygenation and Inhibits Hypoxic Gene Expression in Patients with Non–Small Cell Lung Cancer. Clinical Cancer Research, 2021, 27, 2459-2469.	3.2	40
18	IGF-1R associates with adverse outcomes after radical radiotherapy for prostate cancer. British Journal of Cancer, 2017, 117, 1600-1606.	2.9	35

#	Article	IF	CITATIONS
19	Buparlisib with thoracic radiotherapy and its effect on tumour hypoxia: A phase I study in patients with advanced non-small cell lung carcinoma. European Journal of Cancer, 2019, 113, 87-95.	1.3	35
20	Identification of vitamin B1 metabolism as a tumor-specific radiosensitizing pathway using a high-throughput colony formation screen. Oncotarget, 2015, 6, 5978-5989.	0.8	33
21	The protease SPRTN and SUMOylation coordinate DNA-protein crosslink repair to prevent genome instability. Cell Reports, 2021, 37, 110080.	2.9	22
22	TOPK modulates tumour-specific radiosensitivity and correlates with recurrence after prostate radiotherapy. British Journal of Cancer, 2017, 117, 503-512.	2.9	20
23	¹⁸ Fâ€fluoromisonidazole uptake in advanced stage nonâ€small cell lung cancer: A voxelâ€byâ€voxel PET kinetics study. Medical Physics, 2017, 44, 4665-4676.	1.6	16
24	Targeting TOPK sensitises tumour cells to radiation-induced damage by enhancing replication stress. Cell Death and Differentiation, 2021, 28, 1333-1346.	5.0	13
25	Personalized Radiation Oncology: Epidermal Growth Factor Receptor and Other Receptor Tyrosine Kinase Inhibitors. Recent Results in Cancer Research, 2016, 198, 107-122.	1.8	12
26	Targeting tumour hypoxia: shifting focus from oxygen supply to demand. British Journal of Radiology, 2019, 92, 20170843.	1.0	12
27	Nucleoporin 54 contributes to homologous recombination repair and post-replicative DNA integrity. Nucleic Acids Research, 2018, 46, 7731-7746.	6.5	11
28	The anti-malarial drug atovaquone potentiates platinum-mediated cancer cell death by increasing oxidative stress. Cell Death Discovery, 2020, 6, 110.	2.0	11
29	External Beam Radiation Therapy and Enadenotucirev: Inhibition of the DDR and Mechanisms of Radiation-Mediated Virus Increase. Cancers, 2020, 12, 798.	1.7	11
30	Investigation of atovaquone-induced spatial changes in tumour hypoxia assessed by hypoxia PET/CT in non-small cell lung cancer patients. EJNMMI Research, 2021, 11, 130.	1.1	9
31	Depletion of signal recognition particle 72kDa increases radiosensitivity. Cancer Biology and Therapy, 2017, 18, 425-432.	1.5	8
32	[18F]FE-OTS964: a Small Molecule Targeting TOPK for In Vivo PET Imaging in a Glioblastoma Xenograft Model. Molecular Imaging and Biology, 2019, 21, 705-712.	1.3	8
33	Associations between cardiac irradiation and survival in patients with non-small cell lung cancer: Validation and new discoveries in an independent dataset. Radiotherapy and Oncology, 2021, 165, 119-125.	0.3	5
34	4D-PET reconstruction using a spline-residue model with spatial and temporal roughness penalties. Physics in Medicine and Biology, 2018, 63, 095013.	1.6	4
35	Whole tumor kinetics analysis of 18F-fluoromisonidazole dynamic PET scans of non-small cell lung cancer patients, and correlations with perfusion CT blood flow. EJNMMI Research, 2018, 8, 73.	1.1	4
36	¹⁸ F-Misonidazole PET-CT scan detection of occult bone metastasis. Thorax, 2016, 71, 97-97.	2.7	3

3

#	Article	IF	CITATIONS
37	Radiation-induced prodrug activation: extending combined modality therapy for some solid tumours. British Journal of Cancer, 2022, 126, 1241-1243.	2.9	2
38	A new roadmap to improve translation of imaging biomarkers. British Journal of Cancer, 2016, 115, 1443-1444.	2.9	1
39	Targeting Tumor Hypoxia. Cancer Drug Discovery and Development, 2020, , 265-299.	0.2	1
40	Reply to †The use of buparlisib as a radiosensitiser: What about toxicity?'. European Journal of Cancer, 2019, 119, 196-197.	1.3	0
41	Elucidating the role of transiently hypoxic tumour cells on radiation resistance. British Journal of Cancer, 2022, 126, 971-972.	2.9	0
42	Automated 96-well format high throughput colony formation assay for siRNA library screen. STAR Protocols, 2022, 3, 101355.	0.5	0